This two-day event, Global Advances in Translational Therapeutics & Biomanufacturing, brings together leading voices from academia, industry, and clinical research to explore how cutting-edge discovery is translated into real-world therapeutic and manufacturing innovation.
Featuring Speakers:Â
- Prof. Garret Fitzgerald, Director of the Institute for Translational Medicine at the Perelman School of Medicine, University of Pennsylvania
- Jack O'Meara, CEO and Co-Founder of Ochre Bio and Aerska
- Prof. Jongkwang Hong, Professor at K-NIBRT and Division of Biological Science and Technology, Yonsei University
- Dr. Ayokunmi Ajetunmobi, Head of Ventures, Pioneer Group
- Prof. Brian Glennon, UCD and Senior Director and Co-Founder of APC Ltd
- Dr. Marie-Angélique Sene, Head of the Vaccine Research Center at the Institut Pasteur de Dakar
- Prof. Jimmy Gollihar, Head of the Antibody Discovery & Accelerated Protein Therapeutics (ADAPT) Laboratory at the Houston Methodist Research Institute
- Prof. Helen McCarthy, Northern Ireland’s Chief Scientific and Technology Adviser, Chair of Nanomedicine at Queen’s University Belfast, and Founder of pHion Therapeutics.
- Dr. Cristina Ruedell Reschke, Lecturer at RCSI and Funded Investigator in the FutureNeuro Research Centre
- Prof. Jaehun Shin, Director of K-NIBRT and Associate Professor, Integrated Science and Engineering Division, Underwood International College, Yonsei University
Panel discussion moderated by Stuart Jackson, Director, Business Consulting, EY:
- Dr. Araz Raoof, Executive Director of the ARC Hub for Therapeutics
- Dr. Montse Daban, Strategic Foresight and International Relations Director at Biocat
- Dr. Noel Daly, Senior Client Advisor at Enterprise Ireland
- Dr. Moayed Hamza, Co-Founder of HAON Life Sciences
Research at NIBRTÂ
NIBRT Research is a world leader in developing innovative technologies that advance biopharmaceutical manufacturing and a resource for the global biopharmaceutical industry. Inspired by the manufacturing challenges facing the industry, NIBRT Research makes transformative discoveries across multidisciplinary areas such as analytical science, cell and genetic engineering, informatics, and bioprocess engineering. These discoveries are utilised to advance the state-of-the-art in their fields and revolutionise the manufacturing of recombinant proteins, vaccines and cell and gene therapies.
NIBRT's recent large scale expansion to our existing facility includes five new laboratories dedicated to research in advanced therapies. This expansion will increase NIBRT’s capability in Advanced Therapy Medicinal Products (ATMPs) including Cell and Gene Therapy (CGT) research and training. The €21 million project is funded by the IDA Ireland and the Government of Ireland and will become an integral part in placing Ireland at the forefront of ATMP research, training and innovation.
About NIBRTÂ
NIBRT supports the growth and advancement of the biopharma manufacturing industry by offering state-of-the-art training and research solutions. Through a unique collaboration between industry, government, and academia, NIBRT opened its world-class facility in Dublin, Ireland in 2011.
The facility was primarily funded by IDA Ireland (Industrial Development Agency), Ireland's inward investment promotion agency, which is dedicated to attracting and developing foreign investment in Ireland. As a result, NIBRT provides an unparalleled training and research experience that was previously unavailable anywhere in the world
